Oruka Therapeutics, Inc.
General ticker "ORKA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $612.2M (TTM average)
Oruka Therapeutics, Inc. follows the US Stock Market performance with the rate: 53.1%.
Estimated limits based on current volatility of 7.7%: low 34.51$, high 40.23$
Factors to consider:
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [17.78$, 43.78$]
- 2026-12-31 to 2027-12-31 estimated range: [11.53$, 30.19$]
Short-term ORKA quotes
Long-term ORKA plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM |
| Operating Expenses | $88.12MM | $122.05MM |
| Operating Income | $-88.12MM | $-122.05MM |
| Non-Operating Income | $4.40MM | $16.62MM |
| Interest Expense | $1.47MM | $0.00MM |
| R&D Expense | $75.06MM | $100.64MM |
| Income(Loss) | $-83.72MM | $-105.43MM |
| Profit(Loss)* | $-83.72MM | $-105.43MM |
| Stockholders Equity | $382.22MM | $471.93MM |
| Assets | $396.02MM | $488.62MM |
| Operating Cash Flow | $-57.84MM | $-88.21MM |
| Capital expenditure | $0.19MM | $0.21MM |
| Investing Cash Flow | $-330.13MM | $-96.75MM |
| Financing Cash Flow | $449.54MM | $170.31MM |
| Earnings Per Share** | $-4.99 | $-2.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.